Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
7 Indonesian airports remain shut due to volcanic ash from Anak Krakatau
Nepal marks national mourning day after deadly flood
Far-right AfD wins historic victory in German state election
At least 5 killed in Amazon Prime Air cargo plane crash in Miami
Israeli strike kills 2 in Gaza, medics say
Bangladesh dengue outbreak accelerates as hospitals come under strain
US peace envoys meet Zelenskyy in Kyiv after Putin talks
US targets three Iranian oil vessels after attack on Navy ships
